As news of substantial negotiations for a potential licensing agreement surfaced, shares of BioRestorative Therapies, Inc. (NASDAQ: BRTX) have surged on the US stock charts. At the latest check during the current market session, BRTX stock was trading up 62.55%, reaching $2.17.
- Progress In Regenerative Medicine
- Novel Therapeutic Strategies
- Industry Interest And Future Prospects
Progress In Regenerative Medicine
BioRestorative (BRTX) said today that it has entered into significant negotiations for the licensing of BioRestorative's allogeneic, commercially available ThermoStem metabolic intellectual property with an unidentified regenerative medicine business.
Prior peer-reviewed preclinical research carried out in association with the University of Utah School of Medicine demonstrated the existence of a clonogenic population of metabolically active adult human brown adipose tissue (BAT) stem cells that are able to expand and differentiate into many lineages in vitro. These cells can functionally differentiate into metabolically active brown adipocytes.
Additionally, preclinical results demonstrated that multipotent brown adipose-derived stem cells (BADSCs) induced to differentiate into brown adipocytes exhibit mature functional properties, including enhanced mitochondrial activity, a critical functional characteristic of BAT. Brown adipogenic potential stem cells (BADSCs) offer a potentially effective novel treatment option for obesity and associated metabolic problems.
Novel Therapeutic Strategies
To further explore this potential, BioRestorative has developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data from high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride, and blood glucose levels compared to saline-only injected controls.
However, no assurances can be made that a licensing agreement will be finalized, whether on commercially reasonable terms or otherwise. BioRestorative does not plan to make additional announcements regarding the license unless and until an agreement is reached.
Industry Interest And Future Prospects
It has been intriguing to observe the scale, scope, and speed with which potential license partners have shown interest in BioRestorative's proprietary off-the-shelf ThermoStem platform. Pioneering animal studies indicated that BADSCs could potentially mitigate weight gain and hyperglycemia associated with high-fat diets.
Furthermore, the 3D scaffolds, capable of maintaining viable transplanted cells for at least five weeks post-implantation, have attracted the interest of commercial-stage regenerative medicine companies, with whom BioRestorative is now engaged in significant licensing discussions.
随着一份潜在授权协议的实质性谈判消息传出,BioRestorative Therapies公司股票(NASDAQ:BRTX)在美国股市走高。在当前市场交易期间的最新检查中,BRTX股票上涨了62.55%,达到了2.17美元。
再生医学的进展
BioRestorative(BRTX)今天表示,已与一家未知的再生医学企业就BioRestorative的异基因、商业可获得的ThermoStem代谢知识产权进行重大谈判。
此前与犹他大学医学院合作进行的同行评审的临床前研究表明,存在一种有代谢活性的成人人体褐色脂肪(BAT)干细胞克隆种群,能够在体外扩增和分化成许多分化系。这些细胞能够在功能上分化为代谢活性的褐色脂肪细胞。
此外,临床前结果表明,诱导分化为褐色脂肪细胞的多能性褐色脂肪来源干细胞(BADSCs)表现出成熟的功能特性,包括增强的线粒体活性,这是褐色脂肪细胞的一个关键功能特性。褐色脂肪潜能干细胞提供了一种潜在有效的肥胖症和相关代谢问题的新治疗选择。
新的治疗策略
为了进一步探索这个潜力,BioRestorative开发了一种3D多孔细胞外基质衍生支架,以实现有效的细胞输送。由3D支架支持的分化BADSC移植受到了高脂饮食NOD-SCID小鼠数据的支持,相对于仅注射生理盐水的对照组,显示出体重、甘油三酯和血糖水平有显著降低。
然而,不能保证授权协议将会以商业上合理的条款达成最终协议。BioRestorative不打算在达成协议之前或之后再作其他公告。
行业板块兴趣与未来前景
观察到潜在的授权合作伙伴向BioRestorative的专有的现成ThermoStem平台表现出的兴趣的规模、范围和速度是令人着迷的。开创性的动物研究表明,BADSCs有可能缓解高脂饮食引起的体重增加和高血糖症。
此外,能够在植入后至少五周内维持可存活移植细胞的3D支架,吸引了商业阶段再生医学公司的关注,与这些公司,BioRestorative现在正进行重大许可讨论。